Cargando…
Local immunomodulation for cancer therapy: Providing treatment where needed
In murine models of cancer, we have achieved efficient systemic activation of tumor-specific T cells by the local administration of a CTLA4-blocking antibody at low doses. Using a slow-release formulation, we could drastically lower the serum levels of the antibody, hence decreasing adverse effects...
Autores principales: | Fransen, Marieke F, Ossendorp, Ferry, Arens, Ramon, Melief, Cornelis JM |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897564/ https://www.ncbi.nlm.nih.gov/pubmed/24490127 http://dx.doi.org/10.4161/onci.26493 |
Ejemplares similares
-
PD-L1 immune suppression in cancer: Tumor cells or host cells?
por: Kleinovink, Jan Willem, et al.
Publicado: (2017) -
Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D
por: Evans, Elizabeth E, et al.
Publicado: (2015) -
Predicting the efficacy of cancer vaccines by evaluating T-cell responses
por: van Duikeren, Suzanne, et al.
Publicado: (2013) -
Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands
por: Chew, Valerie, et al.
Publicado: (2013) -
Why should we need the gut microbiota to respond to cancer therapies?
por: Viaud, Sophie, et al.
Publicado: (2014)